Desferrioxamine related maculopathy: a case report.
Desferrioxamine is used for the treatment of chronic iron overload, acute iron poisoning, and certain anaemias. Ocular toxicity secondary to prolonged treatment with desferrioxamine may result in night blindness, visual field constriction, cataract, pigmentary retinopathy and optic neuropathy. To avoid such complications an ophthalmic screening has been suggested for patients taking desferrioxamine. We report an 81-year-old patient who developed irreversible ocular toxicity despite undergoing ophthalmic screening.
Arora
Anita
A
The Western Eye Hospital, London, United Kingdom. anitarora@aol.com
Wren
Siobhan
S
Gregory Evans
Kevin
K
D000368:Aged; D000369:Aged, 80 and over; D001284:Atrophy; D003676:Deferoxamine / Q000009:adverse effects* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D005902:Glaucoma, Open-Angle / Q000150:complications; D006801:Humans; D007501:Iron / Q000502:physiology; D007502:Iron Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy / Q000209:etiology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000628:therapy; D008266:Macula Lutea / Q000473:pathology*; D008268:Macular Degeneration / Q000175:diagnosis; D010857:Pigment Epithelium of Eye / Q000473:pathology; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D065227:Transfusion Reaction; D014786:Vision Disorders / Q000209:etiology; D014792:Visual Acuity
D007502:Iron Chelating Agents; D007501:Iron; D003676:Deferoxamine